Abstract 99P
Background
Patients with chemotherapy-responsive advanced biliary tract cancer (BTC) are usually observed post 6 months of gemcitabine-based therapy, though most progress within a short time-span and there is limited prospective evidence for maintenance strategies.
Methods
The study is an integrated phase II – III randomised clinical trial (Clinical Trial Registry of India number: CTRI/2017/10/010112) conducted at 2 centres in India. Eligible patients with advanced BTC who had responsive or stable disease status post 6 months of gemcitabine – based chemotherapy were randomly assigned (1:1) to either observation arm (O) or intervention arm (BEER), which was a combination of Bevacizumab 5 mg/m2 IV every 21 days plus erlotinib 100 mg once daily, . Both arms were continued till disease progression, significant toxicity or patients choice. The primary endpoint of the phase II component was progression free survival, measured from randomization into the trial.
Results
Between May 2021 and November 2022, 98 patients (O: 48; BEER: 50) comprising 78 patients with gallbladder cancer (GBC) and 20 patients with cholangiocarcinoma (CC) were randomised with all 98 patients included in the final analysis. With a median follow up of 11.2 months, patients in the BEER cohort showed an improved PFS compared to the observation cohort [5.2 months (95% CI: 3.4-6.9) vs. 3 months (95% CI: 2.5 - 3.5); p=0.004]. The CC cohort tended to derive greater benefit from BEER (6.7 months vs. 2.2 months) than the GBC cohort (4.3 months vs. 3 months). There were no grade 3 or grade 4 adverse events noted, though temporary cessation of erlotinib was required due to grade 2 skin rash in 7 patients (14%), and grade 2 oral stomatitis in 1 patient (2%).
Conclusions
The combination of bevacizumab and erlotinib improves progression free survival in patients with chemotherapy responsive advanced BTC in this phase 2 clinical trial. The ongoing phase III component of the study will evaluate whether the significant benefit in PFS translates to improvement in overall survival.
Clinical trial identification
CTRI/2017/10/010112.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Cadilla Pharma Pvt Ltd (supported bevacizumab) Dr. Reddy's Lab pvt Ltd (supported bevacizumab) LUPIN Pharma pvt Ltd Intas pvt Ltd.
Disclosure
A. Ramaswamy: Financial Interests, Institutional, Research Grant: Cipla Health Limited, Dr Reddy Laboratories, Zydus Lifesciences. V.S. Ostwal: Financial Interests, Institutional, Funding, IIS: Cadilla Pharmaceuticals pvt Lts, Reddy's pvt Ltd, Lupin, BDR; Financial Interests, Personal, Invited Speaker, GI ESMO 22: AstraZeneca; Financial Interests, Institutional, Advisory Board: Mankind, Natco. All other authors have declared no conflicts of interest.
Resources from the same session
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17